According to MRFR analysis, the global biopharmaceutical
excipients market is expected to register a CAGR of~6.8% from 2021 to 2027 and
is expected to hold a value of ~USD 3,114.6 million by 2027
The global biopharmaceutical excipients market is driven by
several factors, such as increasing demand for oral formulations across the
globe, rising demand for customized medicines, and an increasing geriatric
population. Other factors such as increasing patients with chronic ailments coupled
with growing life expectancy are driving the production of biopharmaceuticals.
In addition, increasing stress, back pains, body aches, and headaches has
augmented the demand for topical type formulation, accelerating the market
growth.
The industry players focus on expanding their global
footprint by strategic partnerships, investing in some company’s stock,
acquisitions, and product launches. For instance, in February 2020, Re Form
Biologics (US) partnered with Millipore Sigma (US) to commercialize excipients
used in biotherapeutics. In August 2019, LBB Specialties (US) announced the
strategic partnership with MEGGLE (Germany)to expand its excipient distribution
channel across the US. In December 2018, Roquette (France) bought a majority
stake in excipient producer Crest Cellose (India) that enabled the company to
expand its product portfolio and presence in the Indian generic pharmaceutical market.
Furthermore, the prominent players focus on new developments, employee
satisfaction, the transformation of their research wings, and expanding their
distribution network. These factors will augment the market growth and will
increase the product demand in the forecast timeline.
Key Players
Some of the in the global biopharmaceutical
excipients market players are Merck KGaA (Germany), Colorcon (BPSI Holdings
Inc) (US), BASF SE(Germany), Associated British Foods plc (UK), Signet
Excipients Pvt. Ltd (IMCD) (Netherlands), Sigachi Industries Limited
(Hyderabad), Spectrum Chemical Manufacturing Corp. (US), Roquette Frères (France),
Clariant (Switzerland), DFE Pharma (Germany), J. Rettenmaier & Söhne Gmbh +
Co Kg (Germany), and Evonik Industries AG (Germany).
Regional Analysis
North America is projected to dominate the biopharmaceutical
excipients market due to the growing adoption of the latest drug manufacturing
technologies, increasing chronic diseases, and expansion of production
capabilities of the industry players across the region. In addition, high investments
were made in the development of new excipient variants to advance the product
portfolio. Furthermore, the key players are involved in collaborations,
mergers, and R&D activities that propel market growth.
Europe embraces the second-largest position in the
biopharmaceutical excipients market due to growing investments in the
pharmaceutical sector and increasing production capacity across the region. In
addition, the region experienced high demands for pharmaceutical products.
Moreover, countries such as Germany, Italy, the UK, France, and Spain have
invested huge amounts in the manufacturing of new vaccines.
Asia-Pacific is anticipated to be the fastest-growing
regional market over the projected timeline due to the rising investment in
pharmaceutical research and production facilities, increasing consumption of medicines,
and supportive government alliances and subsidy schemes. In addition, the
availability of highly skilled research employees and an economical workforce
is creating opportunities for the industry players.
Furthermore, the market in the Rest of the World is gaining
importance due to the rising number of investors, growing geriatric population
in countries such as Chile and Argentina, and expansion of the pharmaceutical
market across Latin America. However, the availability of counterfeit
pharmaceutical goods is hampering the biopharmaceutical excipient market. The
pharmaceutical companies aim atinvesting in the Middle East & Africaregion
owing to its technologically advanced labs and other research infrastructures.
Countries such as Saudi Arabia and the UAE are hiring employees throughout the
globe to advance their pharmaceutical market.
Segmentation
The global biopharmaceutical excipients market is
categorized into product and formulation. Based on the product category, the
market has been segregated into solubilizers & surfactants/emulsifiers,
polyols and carbohydrates, and specialty excipients. The carbohydrates segment
is expected to hold a considerable share of the market in 2021. Increasing
R&D activities for the development of lipid and protein excipient-based
corona vaccines is fueling the market demand. In addition, the high demand for
carbohydrate-based medicines for the infant segment is propelling the
biopharmaceutical excipient market.
Based on formulation, the global biopharmaceutical excipients
market has been classified as oral, topical, and injectables. The oral segment held
the major share in 2020 due to the easy intake procedure and availability of
oral medicines throughout the hospitals and retail stores. Additionally, the
demand for oral and topical formulations is accelerating due to the growing
preference for on-the-go treatment and ambulatory treatment services coupled
with increasing cases of trypanophobia.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
The Wall